Thomas Polen on GLP-1 market
From Becton Dickinson and Co ($BDX) Q2 2026 Earnings Call · · Castify Earnings Call
“We have over 80 GLP-1 biosimilar deals signed to be in our devices. And those are not just in our syringes, but they also could be deals that we've signed with our auto-injectors or with our pens, which come at higher ASPs, several times higher ASP than when we just sell a syringe, which is really what we're selling today in GLP-1. So the value opportunity for BD in biosimilars is actually higher per dose than it is with the novel GLP-1s that exist in the market today.”
On , Thomas Polen, President, Chief Executive Officer & Chairman at Becton Dickinson and Co, spoke about GLP-1 market during Becton Dickinson and Co ($BDX) Q2 2026 Earnings Call on Castify Earnings Call.
About Thomas Polen
Thomas Polen, chairman, CEO, and president of Becton Dickinson, has been leading the company through a period of strategic transformation. In early 2025, BD announced its intention to separate its biosciences and diagnostic solutions business, a transaction Polen said would "unlock meaningful value for our shareholders." The separation was completed in early 2026, with the business combining with Waters Corporation. Polen described the new BD as a "pure play medtech company" with a "deep innovation pipeline" and a "best-in-class consumables revenue profile of over 90%." He stated that the company's growth strategy is supported by "BD excellence," a capability he said is driving gross margin improvement, operating effectiveness, and cash generation. Throughout the earnings calls, Polen emphasized a focus on commercial and innovation excellence, disciplined capital allocation, and returning capital to shareholders. He noted that the company views its stock as undervalued and has prioritized share repurchases, including a $2 billion buyback in the second quarter of fiscal 2026. Polen also highlighted growth in high-margin areas such as advanced patient monitoring, pharmacy automation, and biologics drug delivery, stating that the company has "over 80 GLP-1 biosimilar deals signed." He said the company is navigating transitory headwinds, including tariff impacts, while maintaining its guidance and investing in sales and R&D.